Wuxi Biologics - Rare Buying Opportunity (BUY, TP HKD60 [125], 14 pgs)
A combination of our newly formed forecast model and Wuxi Bio’s recent commentary, means we are increasingly confident on Wuxi’s ability to deliver our forecasted 18% sales growth this year and 16% CAGR sales growth to 2028. We see significant upside to our forecast from the $6.5bn milestone pool of which we include only $200m by 2028 and we include zero royalty revenue. Gross margins are likely to remain depressed for some time as a number of new plants come on stream and take time to ramp up. Whilst we’re below cons., we view Wuxi as a rare mid-term buying opportunity. 100% upsideFor access to the full note , please contact Naresh Chouhan ( )
Provided by our team of experienced analysts, our work is idea driven, based on independence of thought, sector expertise, and firmly focussed on fundamentals and valuation.
New Street Research is an independent, partner-owned, research firm specialising in equity and debt research. Our equity research embraces the following sectors:
- Pan European Telecom Services and Cable
- US Telecoms, Cable, Satellite and Towers
- Global Emerging Market Telecoms
- Japan Telecoms
- Asian Internet
- Pan European Healthcare
- Global healthcare thematic research
We provide debt research on:
- Pan European Telecom Services and Cable
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.